Roche stops development on an Angelman therapy due to disappointing efficacy, says it’s seeking external partner

Roche is not mov­ing for­ward with its ear­ly-stage treat­ment can­di­date for An­gel­man syn­drome, the com­pa­ny con­firmed to End­points News, af­ter ad­vo­ca­cy groups post­ed about the halt on Wednes­day.

The Swiss drug­mak­er no­ti­fied pa­tients on Wednes­day that it has “ini­ti­at­ed a search” for an ex­ter­nal par­ty to take over work on its in­ves­ti­ga­tion­al An­gel­man syn­drome drug ru­gonersen, an an­ti­sense oligonu­cleotide. The study’s prin­ci­pal in­ves­ti­ga­tors are in­form­ing par­tic­i­pat­ing fam­i­lies, the com­pa­ny said, and the drug can be made avail­able to them un­til Feb­ru­ary of next year.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters